Auropharma in focus after USFDA issues observation

Aurobindo Pharma shares are likely to remain in focus on August 24 after the company received one observation from the US Food and Drug Administration (USFDA) following an inspection of its Telangana facility. The USFDA conducted a routine inspection of AuroPeptides, the company’s arm engaged in manufacturing peptide APIs, from August 17 to 21, 2026. The inspection concluded with a single observation related to facility and equipment maintenance. Importantly, the observation does not involve data integrity or related Good Manufacturing Practice compliance issues. The company said corrective action was initiated during the inspection and that a formal response will be submitted within the stipulated timeline. Earlier, Aurobindo Pharma received the Establishment Inspection Report for its Raleigh plant in North Carolina, USA, with the facility classified as “Voluntary Action Indicated”. Meanwhile, the company reported a strong performance for Q1. Net profit rose 25.2% year-on-year in the corresponding quarter last year. Revenue increased 16.3% year-on-year. EBITDA grew 17.3% year-on-year. The EBITDA margin improved to 21% from 20% a year earlier. Overall, the limited nature of the latest USFDA observation, along with the company’s strong Q1FY27 financial performance, is likely to keep Aurobindo Pharma shares in focus during Monday’s trading session.